ENHERTU redujo en un 72% el riesgo de progresión de la enfermedad o muerte en pacientes con este tumor comparado con trastuzumab emtansina (T-DM1), según los datos presentados en ESMO
Los datos presentados en la 17ª Conferencia Internacional sobre Cáncer de Mama destacan el potencial de los ADC para el tratamiento de este tipo de tumores
Trastuzumab deruxtecan se basa en el estudio fase II DESTINY-Breast01 que mostró respuestas clínicamente significativas y duraderas en pacientes con este tumor previamente tratado
Este sitio web utiliza cookies propias y de terceros para elaborar información estadística y poder mostrarle publicidad relacionada con sus preferencias a través del análisis de su navegación. Ver detalles >Aceptar
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
